42
46
30
40
26
12
32 Cover Story
14
Product Launches
38
This issue is supported by a cover story titled ‘Analytical Industry’s contribution for Affordable Healthcare’ by Srushti Sanghavi-Shah, Manager Technical Sales and Support Nanghavi Chromatographic Solutions Pvt. Ltd.
The edition also covers recent Healthcare news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry
Featured Article
Milan Paleja to head Novartis India's pharmaceuticals 28 business
22
In the exhibitions highlights we have covered a few major press releases. One of them is titled “Mumbai to host analytica Anacon India and India Lab Expo in April 2018.” For more, please check inside.
NEW DELHI: Novartis India has appointed Milan Paleja as its new president, the company said in a release. He will succeed Jawed Zia, who left the drug maker in March for rival Abbott India
Asia Labex Chennai: 2018
Dr Reddy's gets EIR from USFDA for Cuernavaca plant in Mexico
18
FENZA EXHIBITIONS had launched its schedule for ASIA LABEX for year 2018 calendar. Chennai is hosting 4th Asia Labex from 19th to 21st April, 2018 at Chennai Trade Centre and Ahmedabad is hosting 5th Asia Labex from 27th to 29th September 2018 at Gujrat University Ground.
28
Drug firm Dr Reddy's Laboratories today said it has received establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico.
Microbioz India April 2018
11
ear friends and readers, I am pleased to bring for you another issue of your favorite magazine Microbioz India. It is a “Laboratory Events Special Edition” for the two Mega Events of Laboratory & Analytical Equipments namely ‘India Lab Expo’ & ‘Asia Labex’ going to be held in Mumbai & Chennai respectively this month. The issue is supported by a cover story titled ‘Analytical Industry’s contribution for Affordable Healthcare’ by Srushti Sanghavi-Shah, Manager Technical Sales and Support Nanghavi Chromatographic Solutions Pvt. Ltd. The article talks about the role of longer lasting and more-cost efficient equipments and consumables used in the manufacturing process of medicines so as to reduce the cost of healthcare and ensure that it is affordable to all. A focus has been laid on the HPLC columns used by the pharmaceutical companies saying that if they last longer, it can hugely contribute to affordability of healthcare. It also discusses about the major challenge faced by R& D Scientists in Pharmaceutical Companies i.e, reproducibility of the same result at numerous sites across the globe for a good number of years. For more information, please check the article. The magazine also brings for you the List of Upcoming Mega Trade Fairs of Laboratory, Pharma & Hospital Industry to update you about the upcoming exhibitions in India & Abroad. In the exhibitions highlights we have covered a few major press releases. One of them is titled “Mumbai to host analytica Anacon India and India Lab Expo in April 2018.” For more, please check inside. Also, we have accommodated the latest market research news collected from worldwide sources to keep you updated with what is going on in the industry. Dear friends and readers, I hope you find some value in the magazine. Once again, I would like to thank you for your invaluable love and support. We are always eager to receive your valuable feedback and suggestions as they help us come with better content each time. For any further value addition, please write to us at editor@microbiozindia.com.
Cover Story
Analytical Industry’s contribution for Affordable Healthcare It is of essence for India to maintain and continually strive for low healthcare cost to ensure that healthcare is affordable for every Indian citizen.
When the equipments and consumables used in the manufacturing if these medicines will be longer lasting and more-cost efficient, the pharmaceutical companies will eventually be able to pass this benefit to its customers. As an example, HPLC columns are used by the count of thousands in the pharmaceutical companies. So, if the HPLC columns last longer, it is contributing to overall affordability of healthcare.
One of the biggest challenge for a R&D scientist is to develop a method of analysis for a drug that will be valid and reproducible in numerous sites across India or abroad when the API or the formulation goes into production after 5 years or maybe even more.
High Reproducibility To develop a method, conduct thorough validation with numerous system suitability tests to ensure that it is indeed a reproducible method throughout the life of the formulation in the market, which in some cases such as paracetamol have been 25 years! Because in this long period, analytical methods and techniques get upgraded, technology is constantly changing and so are suppliers of silica for chromatography.
Microbioz India April 2018
14
Cover Story
Today, most HPLC column manufacturers procure the silica for chromatography from different sources, pack the columns and bring them to the market. Thus, a change in the silica source or the slight change in chemistry at the silica producer’s end may lead to variations in the method that has been developed a few years ago. Thus, there is a need for a highly reproducible HPLC column provider that will meet this need of the pharmaceutical companies. Nanghavi’s core strength as a Swedish-Indian joint-venture company is that we are end-to-end providers. We make our own silica, functionalize it ourselves, pack our own columns and sell our own columns. This end-to-end production capability gives us the control over specifications which in-turn yields high quality, highly reproducible HPLC columns.
Increased Life of HPLC columns NLAB Saga™ proprietary technology for sturdy silica backbone leads to about 15-18% longer life of KANAK HPLC columns as compared to other HPLC columns. Stronger silica backbone means that pore channels within the individual silica particles are mechanically and chemically sturdy enough to be resilient towards harsh conditions like ultra low acidity or highly alkaline pH or even fluctuating temperature of the mobile phase. In this month of numerous Analytical tradeshows and the beginning of the financial year, we at Nanghavi would like to encourage the various analytical chemists to look at how they can contribute to affordable healthcare in their own way. Authored by:
Srushti Sanghavi-Shah
Manager Technical Sales and Support Nanghavi Chromatographic Solutions Pvt. Ltd. Srushti.sanghavi@nanghavi.com
Microbioz India April 2018
16
Event Post
Asia Labex Chennai April 2018: Premier Exhibition for laboratory professionals FENZA EXHIBITIONS had launched its schedule for ASIA LABEX for year 2018 calendar. Chennai is hosting 4th Asia Labex from 19th to 21st April, 2018 at Chennai Trade Centre and Ahmedabad is hosting 5th Asia Labex from 27th to 29th September 2018 at Gujrat University Ground. Asia Labex is became the most popular and biggest exhibition in India for laboratory and analytical sector and generated keen interest among laboratory professionals worldwide. The focus area and participants profile in the show are mainly analytical instrumentation, chromatography & spectroscopy, biotechnology, laboratory technology, life sciences, laboratory consumables & chemicals, molecular & clinical diagnostics, nanotechnology, testing & measuring, filtration and educational lab instrumentation.
It will offer the exhibiting companies to not only present their innovations, products and services but to meet with the key decision makers and find the leads and confirmed orders. Attendees will have an unique opportunity to not only have the entire spectrum of the laboratory industry in one place, at one time, providing them total solution but an ideal platform to learn industry insights, connect with peers and grow professionally.
Why Chennai- Tamil Nadu With a dynamic leadership, the nation is steering to new dimensions in the field of Biotechnology, Research, Environment and Pharmaceuticals and more to emerge as a land of immense professional opportunities.
Industry Highlight Microbioz India April 2018
18
Event Post The First Pharma SEZ approved by Govt. Of India is in Tamil Nadu. 10 US FDA approved, 10 UKMHRA approved and over 300 WHO GMP approved manufacturing units in Tamil Nadu. Thrust areas of Tamil Nadu’s biotechnology industry include healthcare, agriculture biotechnology, industrial enzymes bioinformatics, contract-research, marine and environmental biotechnology.
There are 150+ exhibitors from 10 countries, 500+ brands and two days conference - LABOTICA with 8 seminar sessions of latest trends & Laboratory technologies. LABOTICA CONFERENCE- A dedicated two day conference on 19th and 20th April that comprises of Product Launch, Technology Transfer and Networking session. With the Industry Leading Analytical & Research Directors, Professors and Head present at Conference- it becomes very important to attend conference & its technical seminar.
Why Ahmedabad- Gujarat
Ahmedabad, is unique in being one of the few cities where tradition and technology co-exist, a revolution that has already attracted MNC and Indian manufacturing giants to set their base here. With a dynamic leadership, the nation is steering to new dimensions in the field of Biotechnology, Research, Environment and Pharmaceuticals and more to emerge as a land of immense professional opportunities.
Industry Highlight: ➢ Amongst Top 15 Pharma Companies- 6 are based at Gujarat. ➢ India boast of World class CRO's and Gujarat has 2 amongst the Top 10. ➢ State of Gujarat boast of 3rd largest produce in ASIA - with an annual growth of 14% ➢ With the increased budget for Healthcare services the investment increased by 7.2%. Fenza Exhibitions Pvt Ltd. will always be striving to innovate new ways to serve our clients to learn, meet and grow. The team at Fenza has carved a name for themselves over the years & is well recognised in the industry for their services. For updates & any other information kindly Visit: www.asialabex.com | call: +91-1147148781 Email: info@asialabex.com
Event Post
Mumbai to host analytica Anacon India and India Lab Expo in April 2018 ➢ One trade fair, two major cities - Mumbai & Hyderabad ➢ Regional edition in Mumbai from 25-26 April ➢ Knowledge based networking and accompanying programs Mumbai: The Indian analytical instrument industry is expected to grow from 0.5 billion EUR to 2.4 billion EUR between 2012-20 having CAGR of 17% and is poised to grow steadily. One of the major drivers for this market is growing regulations to ensure high-quality products which are in-turn making end-users more quality aware; this unquestionably comprises of the pharma, chemical, food & beverages, R&D and allied industries – where the quality needs to be conserved from molecular level; the demand for laboratory analytical instruments is assured to intensify. In order to capitalize on this growth opportunity, Messe Muenchen India announced a regional edition of analytica Anacon India and India Lab Expo, the market leading trade fairs for laboratory technology, analysis, biotechnology and diagnostics in Mumbai for the very first time. The trade fair is
scheduled for April 25-26, 2018 at Bombay Exhibition Centre. The flagship edition of the trade fair is scheduled from September 6-8, 2018 at HITEX Exhibition Centre, Hyderabad. Analytica Anacon India& India Lab Expo brings together internationally renowned manufacturers, laboratory users, consultants and key government officials on one platform to discuss best practices and seek solutions to some of the most pressing challenges related to the industry and research.
Mumbai: The power centre of Western India The financial and economic capital of India, Maharashtra is the nerve-center to many industries including Food processing, chemical, and pharmaceutical, biotechnology and many others.
Microbioz India April 2018
22
Event Post The Mumbai edition is anticipated to bring together over hundred exhibitors and expects over 3,500 trade visitors in just two days. The multifacet list of exhibitors will showcase solutions from incubators, stability chambers and chemicals to laboratory furniture among many others. The exhibitors include Airtech Corporation, Art Lab Equipments, Beijing Shuguangming, Eppendorf India Limited, Glassco Laboratories Equipments Pvt. Ltd, Hally Instruments, Oxford Lab Chem, Sarstedt AG & Co. KG, Shimadzu Analytical & Agilent Technologies to name a few. Bhupinder Singh, CEO of Messe Muenchen India is delighted with the response of this debut edition: “We are already on the trajectory of putting up a well-executed trade fair welcoming the response of our exhibitors for the Mumbai edition and we are sure to pool in the rightly establisheds et of buyers and customers for our esteemed participants.”
Networking & accompanying programs The trade fair will host a range of supporting programs including Bio Pharma Landscape Conference focusing on in-depth discussion on the development, challenges and implementation of quality standards pertaining to bio-pharma process, Anacon Technology Showcase (Seminar) on
discussions pertaining to analytical technologies ranging from chromatographs to life sciences and more. “Business match-making is one of the key highlights of our trade fairs. At our BuyerSeller Forum, the exhibitors greet-meetconnect with key buyers and decision makers from the industry on a one-to-one level to explore new and promising business opportunities with each other.” concluded Mr. Singh.
One show, two cities: analytica Anacon India and India Lab Expo will take place in Mumbai (April 25-26 at Bombay Exhibition Centre) and in Hyderabad (September 6-8, 2018 at HITEX Exhibition Centre). Visit www.analyticaindia.com information. For PR and media queries contact: Siddharth Narain +91-9971600355 siddharth.narain@mm-india.in
for
more
Business News
Get ready, Pfizer HQ staffers: You’re moving on up to a slick new Spiral skyscraper
15 floors. No word on which floors, exactly; the new building will boast 65 stories. The Post reported last year that Pfizer would take 800,000 square feet in the new building, though Pfizer’s announcement didn’t specify. When its potential headquarters move went public last year, spokeswoman Joan Campion said some of the Manhattan employees may relocate to other facilities in the area, of which Pfizer has several.
It’s official: Pfizer’s New York headquarters will move to Hudson Yards and its slick new skyscraper, The Spiral. Left behind will be the 42nd Street building Pfizer has called home since 1961, but few employees are likely to be heartbroken when they set up their desks in the new building. The current HQ is dated and, compared with newly minted pharma digs elsewhere, less than tech savvy. Not so at The Spiral, which is glitzy on the outside and features glass curtain walls and hanging gardens, and is ready for customimprinting on the inside. News of the potential Hudson Yards move first emerged in the New York Post months ago, and Pfizer said Tuesday it had inked a 20-year lease on
And if the new headquarters follows the pattern of other recent Big Pharma moves and reboots, it’ll try to do more with less space, with ad hoc workstations where employees who aren’t in the office daily can work when they do enter the building. That approach hasn’t been universally popular at other next-gen facilities, however, or so we hear from some roving workers themselves. The newer home bases also feature scads of open spaces, designed to mix up staffers who might not normally interact. That’s for innovation purposes. Ideas come from everywhere, or so the thinking goes, but if they don’t get to the right person, they can’t come to fruition.
Microbioz India April 2018
26
Business News It sounds as if Pfizer will be going in a similar direction. “In relocating our headquarters, we sought to provide our colleagues a modern, stateof-the-art headquarters that would foster greater collaboration and innovation in a vibrant neighborhood in Manhattan,” Albert Bourla, Pfizer’s COO, said in Tuesday’s statement. Pfizer staffers will have to wait for awhile to look out those windows, however. The first moves are slated for 2022. On the bright side, however, that’ll give employees plenty of time to start training to be ready for lunchtime run; the building links up to the High Line elevated park. In the meantime, Pfizer is trying to unload that 42nd Street building, with its 34 floors and 1 million square feet of space. Story Source / Credit: https://www.fiercepharma.com Author: Tracy Staton
Milan Paleja to head Novartis India's pharmaceuticals business NEW DELHI: Novartis India has appointed Milan Paleja as its new president, the company said in a release. He will succeed Jawed Zia, who left the drug maker in March for rival Abbott India
He is a graduate from Bombay University and holds a Cost Accountants degree from the Institute of Cost Accountants of India. Story source and Credit: Economic times
Dr Reddy's gets EIR from USFDA for Cuernavaca plant in Mexico
Drug firm Dr Reddy's Laboratories today said it has received establishment inspection report from the US health regulator for its Cuernavaca facility in Mexico. The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico by the United States Food and Drug Administration (USFDA) was completed with zero observations.
"we have received an Establishment Inspection Report (EIR) from the USFDA, for the above-referred facility," Dr Reddy's Laboratories said in a filing to the BSE.
Paleja, previously president and head of pharmaceuticals for Novartis Indonesia, will also head Novartis India's pharmaceutical business, according to the firm. "While in Indonesia, he pioneered innovative access models, turned around the business and laid the foundation for future growth,"
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings. Story source and Credit: Economic times
Microbioz India April 2018
28
Business News
What Zostavax? GSK's Shingrix eclipses Merck shingles shot with massive market-share steal GlaxoSmithKline's Shingrix is on track to rule the U.S. shingles vaccine market once monopolized by Merck & Co.’s Zostavax, just five months after it was approved by the FDA. By mid-March, the GSK shot had staked out a huge chunk of the shingles-shot field, according to an IQVIA tally based on about half of all prescriptions. As cited by a Monday note from Deutsche Bank analysts, Shingrix scripts accounted for 90% of that IQVIA universe. Meanwhile, Zostavax prescriptions over the same period plummeted by more than 80%. It now begs the question: Will GSK eventually push Merck out of the U.S. shingles market, just as Merck’s Gardasil family of HPV shots once drove away Glaxo's Cervarix? That, of course, remains to be seen. What's evident now is that Shingrix has made a swift market grab,
and it probably has a CDC recommendation to thank for that feat, at least partly. After an Advisory Committee on Immunization Practices’ decision in October, the CDC officially recommends Shingrix over Zostavax to prevent herpes zoster. Plus, the agency expanded its shingles vaccine recommendation to cover adults 50 and older, rather than 60 and older—and recommends Shingrix even for people already vaccinated with Zostavax. That's quite a recommendation: GSK estimates that it gives Shingrix a market of 100 million people in the U.S. alone. It doesn't hurt that Glaxo moved Shingrix into pharmacies quickly. In March, Shingrix had already hit the shelves at most CVS, Walgreens and Duane Reade stores across the U.S.
“Our focus is now getting all of the ducks in a row so that when a patient walks into the pharmacy and asks for the vaccine, it’s in stock, it’s reimbursed, and the healthcare provider knows how to give it,” Luke Miels, the company’s president of
Microbioz India April 2018
30
Business News
global pharmaceuticals, said on a recent conference call. The GSK shot is also believed to be more effective, though no head-to-head studies have pitted the two vaccines against each other. In phase 3, the two-dose Shingrix showed that it is 97.2% efficacious in those age 50 and older. The CDC says the one-dose Zostavax can reduce shingles risk by 51%. If there's one problem with those numbers, it's dosing. Deutsche Bank analysts cautioned that Shingrix's twodose schedule might ultimately hamper sales. Signs of Shingrix’s rise—and hence Zostavax’s fall— were already showing up late last year. For the fourth quarter, GSK reeled in about $30 million in Shingrix sales, while Merck's Zostavax revenue dropped 45% to $121 million. As one of the key products CEO Emma Walmsley is counting on for revenue growth, Shingrix has been moving fast around the world, too. Globally, it was first approved in Canada and was also greenlighted in Europe and Japan on March 23. Analysts also have high expectations for the shot. A recent report from Clarivate Analytics puts Shingrix sales at $1.37 billion by 2022, which is twice the $668 million Zostavax returned for Merck last year. Story Source / Credit : https://www.fiercepharma.com Author : Angus Liu
Teva's M&A-gone-wrong lawsuit over Rimsa deal nets a paltry settlement So much for the forceful response Teva promised when it claimed the former owners of Mexican generics buy Rimsa committed fraud.
After a heated legal battle and public exchange of accusations, the two sides have settled, leaving Teva with only an “insubstantial sum,” the exact amount of which is still unknown, Israeli newspaper Globes reported.
The lawsuit’s conclusion follows a New York judge's move last summer to dismiss Teva’s fraud claims surrounding Rimsa’s previous owners, brothers Fernando Espinosa Abdala and Leopoldo de Jesus Espinosa Abdala. But that decision didn’t completely reject the Israeli drugmaker’s breach-of-contract allegations, leaving the door open for Teva to score a few million dollars in compensation, Globes noted. Microbioz India April 2018
32
Business News
Now, however, Teva has confirmed that the episode is in the past, closing the door on one of two expensive and disastrous purchases from 2015. With all the havoc and debt problems wreaked by Teva’s $40 billion Actavis generics buy—which the company inked shortly before the Rimsa deal—it was easy to overlook the latter debacle. But the purchase, meant to increase Teva’s emerging markets footprint and considered expensive at the time, has already resulted in write downs of over $1 billion, and even more could be on the horizon, according to Globes. The Rimsa buyout turned sour in 2016, shortly after the $2.3 billion deal closed. That’s when Teva said it “became aware of violations perpetrated by the sellers” and accused Rimsa of concealing fraud violations and misleading its buyer. Rimsa, for its part, saw things differently, and it pointed the finger at Teva for concocting false fraud claims that would help it squirm out of the deal. It chalked Teva’s actions up to “buyer’s remorse,” adding that the company didn’t understand the Mexican market—or what it was getting itself into—before it made its entry. Teva “now wants its money back because otherwise Teva knows that its management will be held accountable by its shareholders,” it said that September. Accountable it has been, but not just because of the M&A blip. Most of Teva’s key leaders have since turned over, with current chairman Sol Barer handing the reins to new CEO and Novo Nordisk veteran Kåre Schultz. Story Source / Credit : https://www.fiercepharma.com Author : Carly Helfand
Ayala notches up $17M in financing to push BMS drug into phase 2 Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of
Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The new company licensed rights to BMS’s gamma secretase inhibitor BMS-906024 in December,
saying it intends to develop the lead drug as a precision medicine for patient populations with diseases affected by Notch activating mutations, including cancer. The deal also included a followup drug in the same "pan-Notch inhibitor" class (BMS-986115), and involved an undisclosed upfront fee to BMS plus milestones and royalties. Both the drugs have passed though phase 1 testing. A spokesperson for Ayala tells us that the new funding will be used to take BMS-906024 (now rechristened AL101) through a phase 2 trial in recurrent or metastatic adenoid cystic carcinoma (ACC) patients with activated Notch pathway that is due to get started in the second half of this year. ACC is a rare cancer most commonly affecting the salivary glands in the head and neck, and has no approved therapies and a poor response to available treatments. The cash injection will also be used to conduct preclinical research to characterize additional indications for which AL101 may be effective, as well as license another product candidate, she adds.
Microbioz India April 2018
34
Business News The Series A is being led by Israel Biotech Fund, which was instrumental in setting up the company last year along with a Moon and Harel Insurance that have also participated in this round. Mutations in the Notch pathway are known to play a big role in a variety of cancers, but developing drugs against the target has been challenging, in part because a lack of selectivity among candidates has resulted in dose-limiting side effects. In 2016 for example OncoMed was forced to halt a phase 2 trial of its Notch drug tarextumab after poor results, subsequently abandoning the drug, while in the prior year Roche pulled gamma secretase inhibitor RO4929097 after a mid-stage trial miss. Discussing Ayala’s plans when the company launched last year, chairman David Sidransky, M.D., said that BMS-906024 looks like a “best in class gamma secretase inhibitor”, adding that it has a strategy it hopes will unlock the potential of the drug in Notch-mutated cancers. “Although most Notch targeted clinical trials have traditionally recruited non-selected populations, our approach is to target patients with specific Notch alterations whose tumors are expected to respond directly to this treatment,” he said. Story Source / Credit: https://www.fiercepharma.com Author: Phil Taylor
Alembic Pharma gets USFDA nod for Acyclovir ointment NEW DELHI: Alembic Pharma today said it has received approval from the US health regulator its Acyclovir ointment USP, used for the treatment of genital herpes.
The company has received approval from the USFDA for its abbreviated new drug application (ANDA) Acyclovir ointment USP, 5 per cent, Alembic PharmaceuticalsNSE 1.09 % said in a BSE filing. The approved ointment is therapeutically equivalent to the reference listed drug product (RLD) Zovirax ointment 5 per cent of Valeant Pharmaceuticals North America LLC. The drug is used for management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients, the company said. As per the IMS data, for twelve months ending December 2016, the ointment has an estimated market size of USD 145 million. Shares of Alembic Pharmaceuticals were trading 0.77 per cent up at Rs 545 on BSE. Story source and Credit: Economic times
Microbioz India April 2018
09
UniFlow Radioisotope Fume Hood
The NEW Radioisotope Fume Hood, engineered to meet the strict requirements for lab work involving radiochemicals. With safety at the forefront, the HEMCO UniFlow Radioisotope Fume Hood is constructed with a welded one piece seamless type 304 stainless steel interior fume chamber with all corners coved for easy cleaning.
The work surface is welded to the fume chamber liner and is reinforced to support weight loads associated to isotope work such as lead barriers and equipment. LED lighting and vertical slide tempered glass sash are standard features. These fume hoods are offered in 48”, 60”, and 72” widths and can be outfitted with a wide selection of accessories including service fixtures, electrical service options, cabinets/tables and suitable exhaust blowers to safely remove hazardous fumes or particulates.
GNA Biosolutions to Showcase PCA Technology for Ultrafast PCR and Pharos V8 instrument at Analytica 2018 GNA Biosolutions GmbH is showcasing the Pharos V8, the world’s first Laser PCR instrument based on the company’s proprietary Pulse Controlled Amplification (PCA) technology at the Analytica trade fair (Booth A3/522) in Munich, Germany from April 10-13. Launched in November 2017, the Pharos V8 delivers ultrafast PCR results in 10 minutes or less. Conventional PCR platforms rely on bulky thermocyclers that limit the speed of the reaction.
Microbioz India April 2018
38
Product Launches The Pharos V8 is the world’s first Laser PCR instrument powered by PCA, a novel patented technology developed by GNA Biosolution.
Key features of PCA
Unique patented technology for ultrafast nucleic acid amplification Utilizes microcyclers in solution as miniature thermal hubs for the PCR reaction Rapid energy pulses control speed, resulting in ultrafast PCR reaction times
Key features of the Pharos V8
First commercially available Laser PCR instrument, based on PCA technology Ultrafast PCR results in 10 minutes or less, on an easy to use interface Universal DNA kit for lab-developed tests (bacterial, human genomic & viral DNA) in both single and multiplex formats
and ultrafast molecular tests based on proprietary technologies protected by a comprehensive patent portfolio. GNA Biosolutions aims to bring the power of molecular technology to any environment by building ultrafast, accessible and useful molecular testing platforms, for the lab and the real world. Story Source / Credit: GNA Biosolutions For more Information: https://www.gna-bio.com/
New Heater Module for Flow Chemistry Glass Static Mixer Chips Lars Ullerich, Managing Director GNA Biosolutions states, "PCA is a completely unique and exciting approach to PCR that takes something fundamental and pushes it further. The Pharos V8 instrument delivers results with high sensitivity and unparalleled speed and makes PCR even more useful; it creates new possibilities for a range of different applications across multiple industries." In addition to the Pharos V8, GNA Biosolutions is implementing Laser PCR in an integrated samplepreparation system, as part of a consortium focused on MRSA detection (KAREL). The company also recently completed successful Laser PCR field tests for Ebola RNA virus detection in Sierra Leone as part of a publicly funded project (FILODIAG).
About GNA Biosolutions:
GNA Biosolutions is a molecular technology company specializing in sample-to-result applications across medical diagnostics, biosecurity, food and water safety, agriculture and life sciences. GNA Biosolutions develops instruments, OEM modules
Uniqsis announces HotChip™ - a new standalone heater module that provides precise temperature control of flow chemistry glass static mixer (GSM) chip reactors. The Uniqsis range of chemically-resistant borosilicate glass chip reactor blocks can be used as static mixers to ensure effective mixing before a coil reactor or to perform fast exothermic experiments such as nitration’s or bromination’s where reaction times are often less than 1 minute. Available in sizes from 270µl to 20 ml - GSM chips from Uniqsis can be used to perform reactions from -80°C to over 225°C. GSM chips up to 2 ml can be operated up to 40-bar and are available in 2-channel or 3-channel configuration. Larger GSM chips of 10ml and 20 ml have a premixing channel followed by a residence domain and can operate up to 10-bar. Incorporating a clear, bright LED display, HotChip™ is very easy to use as a standalone module. Simply 'push-to-set' and 'push-to-start' using the rotary controller. Alternatively, HotChip™ can be remotely controlled using a FlowSyn flow reactor system, a Binary Pump Module™ or using the powerful Uniqsis FlowControl™ system control software. Microbioz India April 2018
40
Product Launches
The HotChip™ insulated cover features a cut-out that allows it to be conveniently removed and refitted without the need to disconnect the fluidic connections. An enhanced cool-down option is available which utilises the low pressure compressed supply available in most laboratory fume hoods to accelerate cooling. Since 2007, Uniqsis has specialised in the design and supply of mesoscale continuous flow chemistry systems for a wide range of applications in chemical and pharmaceutical research. The company’s aim is to make flow chemistry easily accessible to both novices and experienced users. Story Source / Credit: Uniqsis For more Information: www.uniqsis.com
INTEGRA Offers Hands-Free Multichannel Pipetting INTEGRA has launched the ASSIST PLUS pipetting robot to put automated pipetting within reach of virtually every lab. Using any INTEGRA electronic multichannel pipette, this compact system offers laboratory automation at an affordable price, providing reproducible and error-free processing while eliminating repetitive manual pipetting tasks. The ASSIST PLUS is designed to offer exceptional flexibility, without the need for dedicated personnel or complex programming.
Click in any of the company’s VIAFLO and VOYAGER electronic pipettes to automate your pipetting tasks. From plate filling and reagent addition to serial dilutions, the system eliminates the influence of human error and inter-operator variability on pipetting, leading to better reproducibility. And, as the smallest and most economical pipetting robot on the market to offer variable tip spacing, it is also ideal for tasks such as
tube-to-plate transfers and plate reformatting. Programmable either directly on the pipette or remotely using INTEGRA’s VIALAB or VIALINK software packages, ASSIST PLUS allows users to quickly and easily set up their protocols, then perform other activities while the robot precisely and reliably carries out the pipetting task. Combined with broad labware compatibility and a range of accessories – from tube racks to high capacity reservoirs – this ensures it fits seamlessly into a variety of laboratory workflows, while still giving you the option to use the same electronic multichannel pipettes for manual tasks as required. Story Source / Credit: Integra For more Information: https://www.integrabiosciences.com
Microbioz India April 2018
42
Product Launches
Characterising Nanomaterials in Food by FFF-ICP-MS Postnova Analytics Postnova Analytics reports on how the inorganic analysis team within LGC (Teddington, UK) has been using the AF2000 Field Flow Fractionation system coupled to Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to characterise nanomaterials in complex food sample matrices. Nanomaterials are known to be present in over 1300 foods and commercial products. As a result of the European Union (EU) recently providing a precise definition of a nanomaterial for regulatory purposes, it has become important to be able to characterise nanomaterials reliably to understand their behaviour in contact with humans and the environment. LGC is an international life sciences measurement and testing company with a history stretching back 175 years, providing reference materials, genomics
ICP-MS (FFF-ICP-MS) being the centrepiece of their multi-modal analytical approach. Dr Goenaga-Infante commented “Over the last 15 years, Field Flow Fractionation (FFF) coupled to ICP-MS and other sizing detectors has proven itself a powerful tool for the characterisation of nanomaterials. For complex samples FFF seemed the ideal choice for matrix separation/sample fractionation, enabling us to achieve selective detection and characterisation of nanomaterials, that otherwise would have been hampered by the matrix components”. Dr Goenaga-Infante added “Having decided that FFF was the technique for us, we approached the two leading FFF manufacturers. We selected Postnova Analytics as our vendor of choice on the basis of their fast response to queries, scientific credibility and knowledgeable technical research assistance. The Postnova AF2000 system works robustly online when coupled with ICP-MS if a systematic approach is undertaken. We very much look forward to extending this collaboration into a partnership for life.” The Postnova AF2000 is a high performance Flow Field-Flow Fractionation (FFF) platform for separation of nanoparticles, macromolecules and proteins in complex matrices such as foodstuffs. Modular in design, the AF2000 incorporates the combined experience, expertise and technological advances from Postnova Analytics' two decades of leadership in FFF. Incorporating a range of FFF modules in a single integrated system to provide universal separation, the AF2000 offers more flexibility, better performance and more robust results than any system before. Story Source / Credit: Postnova For more Information: http://www.postnova.com/
solutions and analytical testing products and services. It is home to several national government roles, including the UK National Measurement Laboratory, the Designated Institute for Chemical and Biomeasurement and the Government Chemist. The inorganic analysis team at LGC - led by Principal Scientist and Science Fellow, Dr Heidi GoenagaInfante - has established world class expertise in sizebased and number concentration analysis of nanomaterials using hyphenated techniques to support the development of reference methods and materials, with field flow fractionation coupled to
Molecular Devices Launches the ImageXpress Pico System Cellular imaging acquisition and analysis system at an affordable price point Molecular Devices, LLC, a leader in protein and cell biology technologies, has announced the launch of its ImageXpress® Pico Automated Cell Imaging System. Building on over 20 years of experience in
Microbioz India April 2018
44
Product Launches the high content imaging space, this compact, affordable imaging system brings the power of both imaging and analysis to the individual lab bench. As the pace of discovery continues to increase, researchers continue to look for tools such as the ImageXpress Pico system that help them to automate
“Significant savings in time over manual microscopy are possible through automating both acquisition steps and post processing of images to deliver data,” said Jeff McMillan, Senior Imaging Product Manager at Molecular Devices. “The system delivers improved efficiency in a single, easy-to-use software package.” manual processes.
Combined with the latest edition of our CellReporterXpress Automated Image Acquisition and Analysis Software, the ImageXpress Pico system takes the guesswork out of setting up a range of assays by offering templates and simple, icon-driven tools to optimize parameters and produce reliable, repeatable data output.
“Over the past few years we have been continuing to invest in cellular imaging technology to bring a full suite of new tools to the research community,” said Greg Milosevich, President of Molecular Devices. “We’re excited to be able to continue to bring powerful tools within reach of every lab, supporting innovation in protein and cell biology.”
ROMIL-UpS™ ultra lc solvents and eluant mixes When you need the ultimate quality, take a look at
ROMIL-UpS™ ultra lc solvents and eluants. ROMIL-UpS™ ultra lc solvents and eluant mixes have been developed to address the challenging requirements of critical analytical applications, such as LC-MS and UHPLC, offering the utmost purity for today’s sensitive instrumentation.
Each ROMIL-UpS™ solvent is carefully produced using the most exacting purification techniques, usetested, and supplied in bottles specially pre-treated to ensure that trace metal impurities remain as low as when freshly manufactured. By controlling both the original purity and the actual purity at the time of opening, problematic adduct formation can be avoided, ensuring the best possible performance for hyphenated techniques. These same exceptional standards apply to ROMILUpS™ off-the-shelf or custom-made eluant mixes, which are ideal for hyphenated chromatography techniques. Every eluant mix is formulated from ROMIL’s ultra purity solvents, helping to achieve the high ionisation efficiencies that ensure reproducible and consistent analytical performance, giving a greater assurance of quality results, first time, every time. When it works well, it's pure chemistry. And when it's pure chemistry, it's ROMIL. For more information, please contact - ROMIL Ltd | The Source | Convent Drive | Waterbeach | Cambridge | CB25 9QT | T +44 (0) 1223 863876
Story Source / Credit: Molecular Devices For more Information: https://www.moleculardevices.com
Microbioz India April 2018
46
Product Launches
VERITY 3011 Isocratic Pump Achieves Nearly Pulse-free Flow Rates for Improved Efficiency Gilson, industry leader in liquid handling,
The VERITY 3011 Pump heads rely on an innovative bayonet design that allows the pump heads to be easily changed without tools. Two pump heads available: the 5 SS for flow rates of 0.01–5 mL/minute and the 10 SS for 0.05–10 mL/minute. Both pump heads support pressures of up to 600 bar (8702 psi).
purification, and extraction laboratory instruments, In a VERITY purification system, the VERITY 3011 pump and other system components are powered by TRILUTION® LC software. When used as a standalone pump, the intuitive touchscreen makes it easy to set up and run the pump in one of three modes: Flow, Dispense, or Program. Gilson has a long history of advancing durable chromatographic system design and today specializes in preparative HPLC, flash chromatography, centrifugal partition chromatography (CPC), and gel permeation chromatography (GPC), with instrumentation that benefits discovery- to processscale workflows. The introduction of the VERITY 3011 Isocratic Pump enhances the Gilson purification portfolio, which also includes columns, fraction collectors, detectors, and system control software.
announces an expansion to its chromatography systems product offering with the introduction of the VERITY® 3011 Isocratic Pump. The new VERITY 3011 Pump broadens the depth of the VERITY purification systems portfolio with advancements over existing pumps including a convenient quick-connect pump head design and intuitive touchscreen control of the instrument. The pump enables reaction monitoring and easily integrates into both analytical and semi-preparative chromatography systems for environmental, food and beverage, and petroleum applications. The VERITY 3011 Pump is a standalone pump with touchscreen control that delivers accurate and nearly pulse-free flow rates, improving overall efficiency and yield. The pump supports pressures up to 600 bar (8702 psi), which are some of the highest in the HPLC market, while the integrated pressure sensor protects system components from damage, decreasing downtime and operational costs.
About Gilson
Gilson is a family-owned global manufacturer of liquid handling, purification and extraction solutions for the life sciences industry. We help researchers advance the pace of discovery by creating easy-to-use lab instruments that improve reproducibility and traceability. Since 1957, we’ve been developing innovative products such as PIPETMAN®. By partnering closely with the scientific community, we’re continuously advancing our product offerings and have added automated pipetting systems and software to our portfolio. Backed by worldwide R&D, service, and support, Gilson strives to enable verifiable science and make lab life easier for our customers. Story source/Credit: Gilson For more information: http://www.gilson.com/
Microbioz India April 2018
48
alarm and user settable AutoOff. An accessory stand is available.
RNI NUMBER: UPENG/2017/73675